HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Terremoto wins $108m in Series C to drive cancer and rare disease programmes

Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.

By Pharmaceutical Technology · Apr 16, 2026 · via Pharmaceutical Technology
Terremoto wins $108m in Series C to drive cancer and rare disease programmes

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
moneyformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
RA Capital banks $75M for a biotech SPAC
MoneyBioPharma Dive ↗
RA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
May 21, 2026
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
MoneyFierceBiotech ↗
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
May 13, 2026
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
MoneyFiercePharma ↗
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
May 12, 2026